Presentation at ECCMID

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, presented the sub-group analysis from its Phase 2, SG016 study on Saturday 23 April in an oral presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held in Lisbon, Portugal from 23-26 April 2022.

The positive results of this Phase 2 study (SG016) in the hospital setting were first announced in July 2020 and published in The Lancet Respiratory Medicine in November 2020.

ECCMID 2022:

Oral Presentation:

Title: Effects of Inhaled interferon beta on hospitalised COVID-19 patients receiving supplemental oxygen

Abstract Number: 02567

Session type: 1-Hour Mini-oral Flash Session

Session name: COVID-19 treatment insights and advances

Session date and time: 23 April 2022 at 11:00 WEST

The poster presentation is now available on the Synairgen website. For further information on ECCMID visit: https://www.eccmid.org/

ATS 2022:

Further analysis of the SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco.